Tinnitus can cause extreme morbidity. Despite many attempts to fi nd a treatment for idiopathic cases, they remain diffi cult to manage. Because nerve injury is one of the suspected etiologies of tinnitus and because gabapentin has been found to be eff ective in treating nerve injuries, some authors have attempted to determine if gabapentin has a role in treating tinnitus. Although gabapentin was found to be ineff ective for tinnitus in these previous studies, to the best of our knowledge no studies have been performed that took into consideration the presence of various accompanying factors and concomitant diseases that might infl uence its eff ect. We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial of gabapentin for idiopathic tinnitus. We treated 40 patients with gabapentin and measured its eff ectiveness by comparing diff erences between pre-and post-treatment Tinnitus Severity Index (TSI) values and tinnitus loudness scores. We also compared these outcomes with those of a group of 40 matched placebo controls. At study's end, we found no signifi cant diff erences between the gabapentin and control groups in mean decreases in TSI value and loudness score (p = 0.85 and p = 0.12, respectively). However, we did fi nd that patients with hypertension, diabetes, and/or dyslipidemia showed a better response to gabapentin than did those with tinnitus alone (p = 0.01). We conclude that although there was no statistically signifi cant diff erence between gabapentin and placebo in treating isolated tinnitus or tinnitus overall, patients with concomitant hypertension, diabetes, and/or dyslipidemia may benefi t from gabapentin.
Introduction
Tinnitus is the perception of sound without an external source. Despite many attempts to fi nd a treatment for idiopathic tinnitus, it remains diffi cult to cure. Th e treatment of idiopathic tinnitus is important because of the extreme morbidity it can cause. Various drugs and procedures have been reported to be somewhat eff ective in treating idiopathic tinnitus, but few have been analyzed in randomized clinical trials. Medications have included anesthetics 1,2 and antiepileptic drugs. 3 Other modalities that have been tried include herbal remedies, vitamins, external sound devices, rehabilitation programs, and neural stimulus. 4 Gabapentin is an adjunctive antiseizure medication that is increasingly being used for a variety of pain disorders. Among the conditions it has been used for are diabetic neuropathy, postherpetic neuralgia, migraine headache, nummular headache, 5 pain following burn injury, 6 phantom limb pain, 7 and chronic pain secondary to Fabry disease. 8 Various investigators, including Piccirillo et al, 9 Witsell et al, 10 and Bakhshaee et al, 11 have shown that gabapentin does not have an overall positive eff ect on tinnitus. However, little has been published on clinical factors that might infl uence the response of tinnitus to gabapentin. We conducted a study to explain the impact of gabapentin therapy on tinnitus in the context of diff erent clinical factors.
Patients and methods
We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial of the eff ect of gaba-Visit us at COSM Booth #306 ENT-Ear, Nose & Throat Journal ■ April 2011 (67.5%) had moderate tinnitus, 21 (26.3%) had severe tinnitus, and 5 (6.3%) had mild tinnitus.
Randomization. A total of 80 patients-31 men and 49 women, aged 20 to 85 years-met our criteria and entered the study. Tinnitus intensity evaluated by audiometry revealed that 46 of them (57.5%) heard a sound that was less than 5 dB; among the rest, intensity ranged from 6 to 25 dB in 13 patients (16.3%) and higher than 25 dB in 21 patients (26.3%). Tinnitus pitches ranged from 0.5 to 10 kHz, with an average of 4.8 kHz (table 2) .
Th e 80 patients were randomly divided into two groups of 40-an active-treatment group consisting of 18 men and 22 women (mean age: 49.9 yr) and a placebo control group made up of 13 men and 27 women (mean age: 52.6 yr).
Th e mean duration of tinnitus was 30.2 months in the active-treatment group and 40.3 months in the control group. Some level of hearing loss was found in 19 of the 40 gabapentin patients (47.5%) and in 27 of the 40 controls (67.5).
pentin on idiopathic tinnitus. Participants were chosen from among patients who had been referred to the otorhinolaryngology department at 22 Bahman Hospital in Mashhad, Iran, for evaluation of tinnitus.
Inclusion and exclusion criteria. To be included in this trial, patients had to be between 18 and 85 years of age, their tinnitus must have persisted for at least 2 months, and their tinnitus must have been nonpulsatile, subjective, and idiopathic. Exclusion criteria included pregnancy, current breastfeeding, the presence of any curable etiology for the tinnitus, bilateral tinnitus, contraindications to gabapentin use, and the consumption of any drugs that might interact with gabapentin or cause tinnitus. Th e study began in mid-March 2006 and extended through mid-May 2008, for a total of 26 months. Patient recruitment and drug therapy were carried out simultaneously.
Baseline evaluations. During recruitment, all prospective candidates provided a complete history and underwent an ear examination. Audiologic testingincluding pure-tone audiometry and determinations of speech reception thresholds and speech discrimination scores-was administered to rule out any curable cause of tinnitus. Magnetic resonance imaging of the brain was obtained to rule out any distinguishable lesions, such as acoustic neuroma and multiple sclerosis.
Tinnitus factors. Patients who met the inclusion criteria completed a form to provide demographic data and information on the nature of their tinnitus-that is, the type of sound, resultant disabilities, accompanying symptoms, acoustic trauma, and accompanying disease (i.e., hypertension, diabetes mellitus, and/or dyslipidemia). Th ese items were collectively classifi ed as tinnitus factors (table 1) . Patients were also asked to describe the duration of their tinnitus, which ranged from 2 to 120 months.
Tinnitus severity index. Patients also completed the Tinnitus Severity Index (TSI) questionnaire, which contains 12 questions (fi gure). For the TSI evaluation, patients are asked to answer each question with one of fi ve possible answers: never (1 point), rarely (2), sometimes (3), usually (4), and always (5) . Possible scores range from 12 to 60, and they refl ect the patient's subjective assessment of the impact of tinnitus on their quality of life.
Loudness score. Patients were asked to subjectively rate the loudness of their tinnitus on a scale of 1 to 10. Th is tinnitus loudness score was used to classify the degree of tinnitus as mild (1 to 4 points), moderate (5 or 6), or severe (7 to 10). Based on these self-ratings, 54 patients Treatment protocol. Th e active-treatment group received gabapentin in ascending doses, starting with 600 mg/day and progressing to a maximum of 1,800 mg/day over a period of 8 weeks. Th e control patients received their placebo according to the same schedule. Th e gabapentin patients were evaluated at the end of each week for drug eff ects and any possible side eff ects. According to the protocol, gabapentin could be stopped at any time a patient reported tinnitus resolution.
At the end of treatment, all patients again fi lled out TSI and loudness score questionnaires. Results were analyzed with the Statistical Package for the Social Sciences (version 15; SPSS; Chicago) soft ware. Th e study design was approved by the Medical Ethics Committee of the Islamic Azad University of Mashhad.
Results
We found no signifi cant diff erences in age and sex between the two groups. Th e effi cacy of gabapentin was determined by comparing pre-and post-treatment TSI values and loudness scores. At study's end, 20 patients in the active-treatment group (50.0%) and 22 controls (55.0%) reported a decrease in or resolution of their tinnitus.
At study's end, the gabapentin group experienced a mean decrease in TSI value of 3.53, and the controls showed a decrease of 2.28. Th e diff erence between the two decreases was not statistically signifi cant (p = 0.85, Student t test). Nor was there a signifi cant diff erence in the mean reduction in loudness score in the two groups: 1.50 in the gabapentin group and 1.43 in the control group (p = 0.12, t test).
Sex. TSI values and loudness scores were analyzed by sex in the gabapentin group. No signifi cant diff erence between the sexes was seen in the mean decrease in TSI value (p = 0.69, t test) or the mean decrease in loudness score (p = 0.50, t test) ( 
Better than Coblation ®
Powered inferior turbinoplasty with the Straightshot® M4 Microdebrider and Inferior Turbinate Blade offers better long-term effectiveness than radiofrequency with Coblation®. [1] [2] [3] [4] In the first three-year study directly comparing long-term efficacy of the two techniques, patients treated with Medtronic's microdebrider experienced significantly better long-term outcomes than those who received treatment with Coblation® radiofrequency. 1 The study found that, compared with preoperative findings, subjective and objective measurements in the microdebrider group had improved significantly at all postoperative assessment times. In the Coblation group, significant improvements were observed at 6 months and 1 year, but not at 2 and 3 years.
When results in the two groups were compared, none of the values for the assessed variables were significantly different at 6 months. At 1, 2, and 3 years, however, all results for both the subjective and objective variables were significantly better in the Microdebrider group. Neither group experienced significant complications from surgery.
Cob oblation n ation tion on n Co

Inferior Turbinate r Inferior Tur rbinate Inferior Tur rbinate Inferior Turbinate r Inferior Tur rbinate I f i T bi I f i T bi t B L A D E D
For further information, please call Medtronic ENT at 800-874-5797 or 904-296-9600. You may also consult our website at www.MedtronicENT.com.
V i s i t u s a t C O S M B o o t h # 5 1 2
at the end of treatment as refl ected by a signifi cantly greater reduction in loudness scores compared with younger patients (p = 0.02, ANOVA). Tinnitus factors. We found no statistically significant diff erences in drug response according to sound type, resultant disability, accompanying symptoms, or acoustic trauma (p = 0.14, p = 0.71, p = 0.80, and p = 0.59, ANOVA, respectively). Likewise, no diff erence was seen with respect to the duration of tinnitus (p = 0.30, ANOVA). We also found that the presence or absence of hearing loss did not infl uence the eff ect of gabapentin on tinnitus (p = 0.27, t test).
We did fi nd a signifi cant diff erence in response to gabapentin among the active-treatment patients who had at least one of the three accompanying diseases we studied (hypertension, diabetes, and dyslipidemia). Th ey experienced more improvement in tinnitus than did those without any of these accompanying diseases (p = 0.01, ANOVA). Th e mean decrease in TSI value in each of the three accompanying disease subgroups was 7.0, compared with a mean decrease of only 2.21 among those patients with isolated tinnitus.
Recurrence. Among the gabapentin patients and controls who reported a decrease in or resolution of their tinnitus at the completion of treatment (n = 20 and 22, respectively), 6 gabapentin patients (30.0%) and 5 controls (22.7%) experienced a recurrence of tinnitus. Th e diff erence between the two groups was not statistically signifi cant (p = 0.59, chi-square).
Discussion
Despite numerous studies, no defi nitive treatment for idiopathic tinnitus has yet been introduced. In our study, we found that gabapentin was eff ective in reducing and even resolving tinnitus in some patients, but that there was no statistically signifi cant diff erence between it and placebo overall. Th e same conclusion was reached by Piccirillo et al, 9 Witsell et al, 10 and Bakhshaee et al. 11 All three of their studies were double-blind and placebo controlled. In addition, Bahmad et al reported that adding GABAergics to benzodiazepines did not improve the treatment of severe tinnitus (GABA = gamma-aminobutyric acid). 12 On the other hand, Bauer and Brozoski found that gabapentin was eff ective in reducing tinnitus loudness in adults who had a history of acoustic trauma. 13 Zapp discussed a case of tinnitus of 10 months' duration that was successfully treated with gabapentin and amitriptyline. 14 Gabapentin is currently being used for a wide spectrum of pain disorders as well as seizure and anxiety. It has a high-affi nity binding site localized at the synapses. Th e stimulated release of neurotransmitters is reduced by gabapentin via binding at calcium channel proteins, and therefore the action of the inhibitory neurotransmitter GABA is imitated. 15 In this study, we found that the response to gabapentin was better in older patients when the measuring variable was the decrease in tinnitus loudness score. Otsuka et al previously reported that intravenous lidocaine led to a better response in patients aged 60 years and older. 1 We also found that patients who had one or more of the three accompanying diseases we studied (hypertension, diabetes, or dyslipidemia) showed a signifi cantly better response to gabapentin than did those with no accompanying disease. Because the inner ear is greatly infl uenced by glucose metabolism, diabetic patients might complain of auditory or vestibular symptoms. 16 Likewise, Pessin et al reported that tinnitus and hearing loss are the most common cochleovestibular symptoms in type 1 (insulin-dependent) diabetes. 17 Th ese fi ndings, together with the documented eff ectiveness of gabapentin for the treatment of diabetic neuropathy, indicate that gabapentin might be the drug of choice for diabetic patients with idiopathic tinnitus, particularly older patients.
Also, Akkuzu et al reported that misoprostol, a prostaglandin E 1 analogue, was eff ective for the treatment of tinnitus in hypertensive and/or diabetic patients. 18 In contrast to the fi ndings of Bauer and Brozoski, 13 our study found that a positive history of acoustic trauma did not aff ect tinnitus response to gabapentin. According to our investigation, other factors-such as tinnitus sound type, accompanying symptoms, and duration-had no infl uence on the eff ect of gabapentin on tinnitus.
If gabapentin is found to be eff ective in relieving tinnitus in any particular case, it probably should be continued at the minimum eff ective dose for the long term or even for the patient's lifetime. Because tinnitus can be eliminated with doses of gabapentin as low as 600 mg/day, we recommend that this drug be started at a low dose and increased slowly to as high as 1,800 mg/day in order to achieve the required result. Further studies in larger groups are needed to confi rm reports that gabapentin is eff ective in diabetic patients.
In summary, we conclude that although there was no statistically signifi cant overall diff erence between gabapentin and placebo in treating tinnitus in our study, patients whose tinnitus is accompanied by hypertension, diabetes, and/or dyslipidemia may benefi t from gabapentin.
